Small cell carcinoma of prostate is rare, with the literature consisting of case reports and small series. The current work analyzes the morphology and immunohistochemistry of 95 cases of prostatic small cell carcinoma diagnosed at our institution. Specimens included 55 needle biopsies, 27 transurethral resections, 4 radical prostatectomies, and 9 biopsies from metastatic sites (some patients with >1 procedure). Patients ranged in age from 44 to 92 years old (mean: 69 y). Although serum prostate-specific antigen (PSA) in some cases was very high (up to 1896 ng/mL), the median value was only 4.0 ng/mL. Of cases with available information, 33/78 (42%) had a history of usual prostatic adenocarcinoma. The interval between the diagnosis of small cell carcinoma and prior usual prostatic cancer ranged from 1 to 300 months (median 25 mo). Pure small cell carcinoma was seen in 54/95 (57%) of cases with the remaining cases admixed with prostate adenocarcinoma. In cases with adenocarcinoma, there was a sharp demarcation between small cell carcinoma and adenocarcinoma in 20.5% of cases; in the remaining cases there was gradual merging of the 2 components. In mixed cases, small cell carcinoma predominated (median: 80% of the tumor); the Gleason score of the adenocarcinoma was Z8 in 85% of these cases. In 61 cases (64%), small cell carcinoma was classic ''oat cell'' morphology with remaining the ''intermediate cell'' variant. Of the 95 cases: necrosis was seen in 40% (2% to 95% of the tumor); giant bizarre cells in 19%; Indian filing in 21%; rosette formation in 29%; focal vacuolated cytoplasm in 18%; and desmoplasia in 20%. Most (88%) of small cell carcinoma were positive for at least 1 neuroendocrine marker. In the small cell carcinoma component, 14/73 (19%) were positive for PSA, 17/61 (28%) positive for prostein (P501S), and 15/59 (25%) positive for prostate-specific membrane antigen, although often very focally. Stains for thyroid transcription factor-1 were positive in 23/44 (52.3%) cases. In this, the largest study of prostatic small cell carcinoma, we highlight the presence of morphologic features that may result in its underdiagnosis. Other more classic histologic features of small cell carcinoma along with rosettes are critical for its accurate diagnosis. P501S and prostate-specific membrane antigen were better in identifying the prostatic origin of small cell carcinoma than PSA, although the majority (60%) of prostatic small cell carcinomas were negative for all 3 markers.
P rostatic small cell carcinoma was first described in 1977 by Wenk et al. 23 It is a rare entity comprising 0.5% to 2% of all prostatic carcinomas, with the literature consisting of case reports and small series. 9 It is critical to recognize prostatic small cell carcinoma, as its therapy differs significantly from that of usual poorly differentiated prostatic adenocarcinoma.
MATERIALS AND METHODS
The current work analyzes the morphologic and immunohistochemical features of 95 cases of prostatic small cell carcinoma diagnosed at our institution. Of the 95 cases, 62 (65.3%) cases were sent to one of the authors in consultation and the remaining sent in for potential treatment at The Johns Hopkins Hospital. Specimens included 55 needle biopsies, 27 transurethral resections, 4 radical prostatectomies, and 9 biopsies from metastatic sites (some patients with >1 procedure).
Morphologic features assessed were the presence of tumor giant cells, Indian filing, rosette formation, vacuolated cytoplasm, stromal reaction, necrosis, perineural and lymphovascular invasion, and relation to admixed usual adenocarcinoma. In addition, the small cell component was characterized into ''oat cell'' and ''intermediate'' cell types. Although the 1981 World Health Organization subclassification of small cell carcinoma into these types is no longer recommended as it lacks prognostic significance, for the purposes of this study we noted the presence of the intermediate type of small cell carcinoma as it could be more readily confused with usual adenocarcinoma of the prostate. 1, 6, 11, 15 For cases with available paraffin blocks or unstained slides, the small cell component was analyzed immunohistochemically at our institution for prostatespecific antigen (PSA), prostein (P501S), prostate-specific membrane antigen (PSMA), and thyroid transcription factor-1 (TTF-1) ( Table 1 ). All the tissues were formalin fixed and paraffin embedded. Immunohistochemistry used standard avidin-biotin peroxidase methodology after antigen retrieval. Positive and negative controls were run in parallel with appropriate results. The staining pattern for PSA and PSMA is cytoplasmic, sometimes associated with luminal staining. P501S shows perinuclear punctate cytoplasmic staining. TTF-1 demonstrated nuclear positivity. Immunostains for neuroendocrine markers (chromogranin, synaptophysin, CD56, and neuron specific enolase) and cytokeratin were performed on some of the cases by contributing pathologists at outside institutions.
Although this study concentrated on the morphologic and immunohistochemical findings in prostatic small cell carcinoma, basic demographic clinical information at the time of presentation was obtained from faxed questionnaires to the patients' urologists. This information included the presence of a prior history and treatment of usual adenocarcinoma of the prostate and serum PSA levels at presentation of small cell carcinoma.
RESULTS

Clinical
Patients ranged from 44 to 92 years old (mean: 69 y). The serum PSA level ranged from undetectable to 1896 ng/mL. The median value was 4.0 ng/mL and the average level was 98 ng/mL. A prior history of usual prostatic adenocarcinoma was noted in 33/78 (42%) of the cases. The Gleason score of the original cancer was not available in most of cases. In 25 of the 33 cases, information on the treatment for the usual prostatic adenocarcinoma was available: hormone therapy (6 cases); radiation (5 cases); radiation and hormone therapy (5 cases), radical prostatectomy (3 cases); or radical prostatectomy with either adjuvant radiation (4 cases), hormone (1 case), or combination hormone and chemotherapy (1 case). In cases with a history of usual prostatic adenocarcinoma, the interval between the diagnosis of small cell carcinoma and prior prostatic cancer ranged from 1 to 300 months with a median of 25 months and a mean of 59 months.
Morphology and Immunohistochemistry
In 61 of the 95 (64%) cases with available slides from rereview, the small cell carcinoma had classic oat cell morphology (Fig. 1 ). The oat cell pattern consisted of uniform small cells, generally larger than lymphocytes, having dense round or oval nuclei, diffuse chromatin, inconspicuous nucleoli, and very sparse cytoplasm. The remaining 34 cases of small cell carcinoma were of the ''intermediate cell type'' composed of cells with nuclear characteristics similar to the oat cell type but with more abundant cytoplasm, slightly larger nuclei, and occasional more visible nucleoli; cells could have a polygonal or fusiform appearance ( Fig. 2 ). Tumor giant cells with large nuclei and smudgy chromatin with a degenerative appearance were noted in 19% of cases ( Fig. 3 ). In 21% of the cases, tumor cells were arranged in an Indian filing pattern ( Fig. 4 ). Rosette formation seen in 29% of cases consisted of both true and pseudorosettes ( Fig. 5 ). Other findings included focal vacuolated cytoplasm in 18% of cases and a desmoplastic or myxoid stromal reaction in 20% of cases ( Fig. 6 ). In 1 case, the small cell carcinoma was admixed with prostatic basal cell carcinoma.
Necrosis was seen in 40% of the cases (2% to 95% of the tumor). Perineural invasion was identified in 32% (30/95) of cases with 18 cases invaded by the small cell component and the remaining 12 cases by usual adenocarcinoma. Lymphovascular invasion was identified in 15% (14/95) of cases: in 11 cases, vessels were invaded by the small cell carcinoma component and in the remaining 3 cases by usual adenocarcinoma.
Pure small cell carcinoma was seen in 54/95 (57%) of cases with the remaining cases admixed with prostate adenocarcinoma. In cases with adenocarcinoma, 20.5% had a sharp demarcation between the small cell carcinoma and usual adenocarcinoma ( Fig. 7 ). In the other cases, there was a gradual merging together of the 2 components ( Fig. 8 ). In the 41 cases with mixed usual adenocarcinoma and small cell carcinoma, the small cell carcinoma predominated in most cases with a median of 80% of the total tumor occupied by the small cell component (range: 1% to 95%; mean: 44%). The Gleason score of the admixed adenocarcinoma ranged from 4 to 10 with 85% of these cases Z8 (3 cases with a Gleason score r6; 3 cases with a Gleason score 7, and 35 cases with a Gleason score 8 to 10) ( Fig. 9 ). In the 54 cases with pure Fig. 10) . In 60% of the cases, the small cell carcinoma component was negative for these prostatic markers (either 3/3 or 2/2 markers studied). In approximately one-half (52.3%) of cases of small cell carcinoma stains were diffusely positive for TTF-1. Immunohistochemical expression of neuroendocrine markers within the small cell carcinoma component was 33/44 (75%) for chromogranin, 27/32 (84%) for synaptophysin, 17/20 (85%) for neuron specific enolase, and 12/13 (92%) for CD56. There was only 1 case negative for all 3 of the neuroendocrine markers chromogranin, synaptophysin, and CD56. There were 6 cases where only 1 or 2 neuroendocrine markers were performed, in which 4 cases were negative for chromogranin and 2 cases were negative for both chromogranin and synaptophysin, respectively.
DISCUSSION
Although the prostate is one of the most common sites of extrapulmonary small cell carcinoma, it is still rare with the largest prior study consisting of 27 cases. 6, 7, 9, 12, 17, [19] [20] [21] 25 All small cell carcinomas including pulmonary and extrapulmonary tumors share the same morphologic features. 4 Classic oat cell morphology consists of tumor cells with scant cytoplasm and round, oval, or spindled nuclei usually smaller than 3 times the size of lymphocytes with fine granular chromatin, and absent or inconspicuous nucleoli. In the current study, 64% of our cases demonstrated this classic histology. However, in the remaining 36% of the cases, tumors were Organization classification of lung carcinomas, was performed in the current study to point out that some of the small cell carcinomas of the prostate have morphologic features that could be more readily confused with usual poorly differentiated adenocarcinoma of the prostate. Currently, when diagnosing small cell carcinoma in any organ, morphologic subtyping is not recommended and both subtypes are reported as ''small cell carcinoma'' as it has been demonstrated that in the lung these 2 types are clinically indistinguishable. 3 Other features, not typically associated with small cell carcinoma including Indian file formation, giant cells, 
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Am J Surg Pathol Volume 32, Number 1, January 2008 vacuolated cells, and desmoplasia, were also seen in a minority of cases. 15 Cases where the small cell carcinoma component merged with nonsmall cell areas would also more likely be underdiagnosed as opposed to cases whether there was a sharp demarcation between the 2 patterns. The likelihood of underdiagnosing small cell carcinoma with these nonclassic morphologic patterns in the prostate is even higher, due to the rarity of the diagnosis of small cell carcinoma relative to the diagnosis of usual prostate adenocarcinoma. In a study of 7 small cell carcinomas of the prostate, Yashi et al 26 found that 4 of the cases were diagnosed as ''poorly differentiated'' or ''Gleason pattern 5'' usual adenocarcinoma. Most of the misdiagnosed cases were cases of combined small cell carcinoma with usual adenocarcinoma. When usual adenocarcinoma is present in a mixed case, the pathologist has a further propensity to consider the small cell component as just poorly differentiated from usual adenocarcinoma. Although the incidence of small cell carcinoma in clinical specimens is estimated to be 0.5% to 2%, autopsy studies reveal small cell carcinoma in 10% to 20% of treated usual adenocarcinoma of the prostate. 13, 20, 22 Although most of the discrepancy in these figure relate to the selection of more advanced and aggressive cases resulting in death, some of the disparity may relate to the underdiagnosis of small cell carcinoma on limited clinical specimens. 14, 26 In cases where the diagnosis of small cell carcinoma is difficult, immunohistochemistry may be helpful, although it typically is not essential for the diagnosis and in some cases may be misleading. Most small cell carcinomas, 94% in our study, express at least 1 neuroendocrine marker. We found that CD56 was the most sensitive (92%), although other markers were also positive in most cases. Negative stains for neuroendocrine markers should not exclude the diagnosis of small cell carcinoma as long as the morphology on routinely stained sections is diagnostic. Conversely, focal immunohistochemical evidence of neuroendocrine differentiation can be seen in an up to 100% of usual adenocarcinomas of the prostate and does not indicate small cell carcinoma. 7 Although Ordonez 18 reported negative immunostains for TTF-1 on all 3 prostatic small cell carcinomas, in the study by Agoff et al 2 all 4 cases were positive for TTF-1 and study by Yao et al 25 15/18 cases positive for TTF-1.
In the current study, 23/44 cases (52.3%) were positive for TTF-1 stain, demonstrating that TTF-1 cannot be used as a marker to distinguish between lung and prostatic origin of small cell carcinoma.
A more recently recognized entity in the prostate that enters into the differential diagnosis of small cell carcinoma is large cell neuroendocrine carcinoma. The tumor cells of large cell neuroendocrine carcinoma are generally large and polygonal with moderate to abundant cytoplasm; nuclear chromatin is coarsely granular and nucleoli are prominent. 10 The tumor is often composed of solid sheets, ribbons, and nests of cells with areas of peripheral palisading. Prostatic large cell neuroendocrine carcinoma is extremely rare, described in case reports and in one small study. [6] [7] [8] 24 In the lung, some studies have shown no significant survival difference between large cell neuroendocrine carcinoma and small cell lung carcinoma when stratified by stage. 4 Although it is useful to differentiate prostatic small cell carcinoma and large cell neuroendocrine carcinoma to determine if the diagnosis of the latter has unique clinical implications, currently there does not seem to be prognostic differences between the 2 entities and both are treated the same. 8 Clinically, when small cell carcinoma metastasizes it may be difficult to determine the origin of the small cell carcinoma. In some cases, there is no history of usual adenocarcinoma of the prostate, and as we have demonstrated serum PSA levels are often not elevated. In metastatic sites, especially in the absence of concurrent usual prostatic adenocarcinoma, prostate-specific immunohistochemical markers may be helpful in identifying the lesions as being of prostatic origin. A novel finding in the current study was that P501S and PSMA were better in identifying the prostatic origin of small cell carcinoma than PSA, although the majority (60.3%) of prostatic small cell carcinomas were negative for these markers.
Our analysis of the morphologic features of small cell carcinoma highlights atypical features that may mislead pathologists into misdiagnosing them as nonsmall cell carcinoma. As small cell carcinoma of the prostate is treated with chemotherapy, as opposed to advanced usual adenocarcinoma of the prostate that is treated with hormonal therapy, it is necessary for pathologists to be familiar with the atypical histologic features of small cell carcinoma along with its immunophenotype so that patients may have the benefit of optimal therapy.
